Redundancy, disaggregation, and the integrity of medical research

Lancet

Volumn 347, Issue 9007, 1996, Pages 1024-1026

  Huston, Patricia ^a   Moher, David ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLICATION; SHORT SURVEY;

EID: 0029881353     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90153-1     Document Type: Article

References (29)

1. Huth EJ. Irresponsible authorship and wasteful publication. Ann Intern Med 1986; 104: 257-59.
2. Kassirer JP, Angell M. Redundant publication: a reminder. N Engl J Med 1995; 333: 449-50.
3. Heinrich K, Eckhard K, Lehmann E, Kinzler E, Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 129-37.
4. Kleiser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15 (suppl): 45s-51s.
5. Marder SR. Risperidone: clinical development: North American results. Clin Neuropharmacol 1992; (suppl); 92A-93A.
6. Meibach RC and the Risperidone Study Group. A fixed-dose, parallel group study of risperidone vs haloperidol vs placebo. Schizophr Res 1993; 9 (special issue): 245.
7. Chouinard G, Jones B, Remington G, et al. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-38.
8. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-34.
9. McEvoy JP. Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry 1994; 55 (suppl): 18-21.
10. Cohen LJ. Risperidone. Pharmacotherapy 1994; 14: 253-65.
11. Huttunen MO, Peipponen T, Rantanen H, Larmo I, Hyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995; 91: 271-77.
12. Marder S, et al. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Jannsen clinical research report on RIS-BEL-7.
13. Marder S, et al. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Janssen clinical research report on RIS-INT-3, 1992.
14. Lindström E, von Knorring L. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 1994; 27: 108-13.
15. Peuskens J, et al. Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind parallel group comparative study versus haloperidol. Janssen clinical research report on RIS-ONT-2, 1992.
16. Peuskens J, on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26.
17. Zinner H, Furget J, Kasper S, Moller H. Evaluation of negative symptoms: results of a double-blind clinical trial with risperidone versus haloperidol. Abstracts from the 5th World congress of biological psychiatry, Florence, 1991. Biol Psychiatry 1991; 29 (suppl): 247.
18. Muller-Spahn R and the International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992; 15 (suppl 1): 90A-91A.
19. Leizorovicz A, Haugh MC, Boissel JP. Meta-analysis and multiple publication of clinical trial reports. Lancet 1992; 340: 1102-03.
20. Gøtzsche P. Multiple publication of reports of drug trials. Eur J Clin Pharmacol 1989; 36: 429-32.
21. McMillen JI. Tolmetin sodium vs ibuprofen in rheumatoid arthritis patients previously untreated with either drug: a double-blind cross-over study. Curr Ther Res 1977; 22: 266-75.
22. McMillen JI. Rheumatoid arthritis: a double-blind study comparing tolmetin sodium with ibuprofen in patients with either drug previously. Curr Ther Res 1982; 31: 813-20.
23. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. JAMA 1993; 269: 2282-86.
24. Rennie D, Flanagin A. Authorship! authorship! guests, ghosts, grafters, and the two-sided coin. JAMA 1994; 271: 469-71.
25. Mahoney MJ. Publication prejudices: an experimental study of confirmatory bias in the peer review system. Cogn Ther Res 1977; 1: 161-75.
26. Schulz KF, Chalmers I, Hayes RJ, Altman DJ. Empirical evidence of bias; dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
27. Schulz KF. Subverting randomization in controlled trials. JAMA 1995; 274: 1456-58.
28. Klein MC, Kaczorowiski J, Robbins JM, Gauthier RJ, Jorgensen SH, Joshi AK. Physicians' beliefs and behaviour during a randomized controlled trial of episiotomy: consequences for women in their care. Can Med Assoc J 1995; 153: 769-79.
29. Gøtzsche P. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Contr Clin Trials 1989; 10: 31-56.